NEW YORK U.S. drug maker Pfizer Inc's $160 billion agreement to acquire Botox maker Allergan Plc was on the brink of being abandoned on Tuesday, after the U.S. Treasury issued new rules on how tax "inversion" deals can be structured.
Allergan's shares were hit considerably hard on Tuesday, showing how the rules that were issued on Monday targeted the biggest inversion attempted to date. The federal government has grappled with a wave of recent inversions by U.S. companies seeking to slash their tax bills by redomiciling overseas...
07:49 Murdoch's Twenty-First Century Fox Bids $14 Billion For UK's Sky10
02:11 Murdoch Pounces on Sky as Lower Pound Makes Takeover Cheaper
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff19
19:34 CEO shift at Coca-Cola could usher in more dealmaking to refresh soda giant's growth13